— Know what they know.
Not Investment Advice

048410.KQ KOE

Hyundai Bioscience Co., Ltd.
1W: +2.9% 1M: +10.3% 3M: -15.4% YTD: -39.0% 1Y: +21.6% 3Y: -41.2% 5Y: -62.5%
₩7,050.00 ($5.24)
+0.00 (+0.00%)
 
Weekly Expected Move ±9.4%
₩5720 ₩6385 ₩7050 ₩7715 ₩8380
KOE · Healthcare · Biotechnology · Tech Score Buy · Power 58 · ₩680.3B mcap · 85M float · 1.87% daily turnover
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap₩680.3B ($505.4M)
52W Range4565-21500
Volume1,195,843
Avg Volume1,593,802
Beta0.77
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJong-Won Choi
Employees54
SectorHealthcare
IndustryBiotechnology
IPO Date2002-08-28
150, Bugahyeon-ro
Seoul, SL 03759
KR
82 70 7008 0114
About Hyundai Bioscience Co., Ltd.

Hyundai Bioscience Co., Ltd. is a biotechnology firm dedicated to creating and commercializing bio-fusion technologies that enable the precise delivery of active compounds throughout the human anatomy. The company offers Vitabrid C12, a novel vitamin C product engineered to provide active vitamin C directly to the skin. Additionally, it is advancing organic-inorganic hybrid technology, which functions as a sophisticated drug delivery system. This system integrates bio-friendly minerals to ensure the targeted and efficient transport of active substances to specific sites, a capability also leveraged in its anticancer drug carrier innovations. The enterprise was established in 2000 and is headquartered in Seoul, South Korea.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms